Industry analysts say AbbVie's recent price cuts to...

...its best-selling anti-inflammatory drug Humira might be a move to secure favorable formulary placement for Skyrizi, the drugmaker's lower-cost alternative to Humira that won FDA approval last month. Efforts to secure preferred placement for Skyrizi "may trigger a price war," Bernstein analyst Ronny Gal recently wrote in a note to clients. For the treatment of plaque psoriasis, Humira currently holds preferred status for 8% of covered lives, growing to 60% including prior authorization and/or step therapy. The drug is classified as a specialty product for 28% of lives. 

SOURCE: MMIT Analytics, as of 5/21/19